Sarecycline
- Generic Name
- Sarecycline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N3O8
- CAS Number
- 1035654-66-0
- Unique Ingredient Identifier
- 94O110CX2E
- Background
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris the US Food and D...
- Indication
用于治疗9岁以上人群的中重度痤疮【美国FDA已批准】。
- Associated Conditions
- Moderate, severe Non-nodular acne vulgaris
- Associated Therapies
- -
Sarecycline Truncal Acne Safety and Efficacy Response
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Angela Moore
- Target Recruit Count
- 10
- Registration Number
- NCT05010538
- Locations
- 🇺🇸
Arlington Research Center, Arlington, Texas, United States
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 300
- Registration Number
- NCT04820673
- Locations
- 🇺🇸
Almirall Site#2, Boston, Massachusetts, United States
🇺🇸Almirall Site #1, Brooklyn, New York, United States
A Pilot Study on the Use of Seysara for Rosacea
- Conditions
- Interventions
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Derm Research, PLLC
- Target Recruit Count
- 100
- Registration Number
- NCT04555525
- Locations
- 🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 490
- Registration Number
- NCT02413346
- Locations
- 🇺🇸
Actavis Investigational Study Site #212, West Jordan, Utah, United States
🇺🇸Actavis Investigational Study Site #129, Encino, California, United States
🇺🇸Actavis Investigational Study Site #113, South Bend, Indiana, United States
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 1034
- Registration Number
- NCT02322866
- Locations
- 🇺🇸
Warner Chilcott Research Site (Site #256), Philadelphia, Pennsylvania, United States
🇺🇸Warner Chilcott Research Site (Site #249), Miami, Florida, United States
🇺🇸Warner Chilcott Research Site (Site #254), San Diego, California, United States
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 968
- Registration Number
- NCT02320149
- Locations
- 🇺🇸
Warner Chilcott Research Site (Site #106), Chicago, Illinois, United States
🇺🇸Warner Chilcott Research Site (Site #102), Miami, Florida, United States
🇺🇸Warner Chilcott Research Site (Site #145), Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.